The comparative safety of opioids for nonmalignant pain in older adults

Daniel H. Solomon, Jeremy A. Rassen, Robert J. Glynn, Katie Garneau, Raisa Levin, Joy Lee, Sebastian Schneeweiss

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

Background: Severe nonmalignant pain affects a large proportion of adults. Optimal treatment is not clear, and opioids are an important option for analgesia. However, there is relatively little information about the comparative safety of opioids. Therefore, we sought to compare the safety of opioids commonly used for nonmalignant pain. Methods: We devised a propensity-matched cohort analysis that used health care utilization data collected from January 1, 1996, through December 31, 2005. Study participants were Medicare beneficiaries from 2 US states who were new initiators of opioid therapy for nonmalignant pain, including codeine phosphate, hydrocodone bitartrate, oxycodone hydrochloride, propoxyphene hydrochloride, and tramadol hydrochloride; none had a cancer diagnosis, and none were using hospice or nursing home care. Our main outcome measures were incidence rates and rate ratios (RRs) with 95% confidence intervals (CIs) for cardiovascular events, fractures, gastrointestinal events, and several composite end points. Results: We matched 6275 subjects in each of the 5 opioid groups. The groups were well matched on baseline characteristics. The risk of cardiovascular events was similar across opioid groups 30 days after the start of opioid therapy, but it was elevated for codeine (RR, 1.62; 95% CI, 1.27-2.06) after 180 days. Compared with hydrocodone, after 30 days of opioid exposure the risk of fracture was significantly reduced for tramadol (RR, 0.21; 95% CI, 0.16-0.28) and propoxyphene (0.54; 0.44-0.66) users. The risk of gastrointestinal safety events did not differ across opioid groups. All-cause mortality was elevated after 30 days for oxycodone (RR, 2.43; 95% CI, 1.47-4.00) and codeine (2.05; 1.22-3.45) users compared with hydrocodone users. Conclusions: The rates of safety events among older adults using opioids for nonmalignant pain vary significantly by agent. Causal inference requires experimental designs, but these results should prompt caution and further study.

Original languageEnglish (US)
Pages (from-to)1979-1986
Number of pages8
JournalArchives of Internal Medicine
Volume170
Issue number22
DOIs
StatePublished - Dec 13 2010
Externally publishedYes

Fingerprint

Opioid Analgesics
Safety
Pain
Hydrocodone
Codeine
Dextropropoxyphene
Confidence Intervals
Oxycodone
Tramadol
Hospice and Palliative Care Nursing
Patient Acceptance of Health Care
Home Care Services
Nursing Care
Medicare
Nursing Homes
Analgesia
Cohort Studies
Research Design
Therapeutics
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Solomon, D. H., Rassen, J. A., Glynn, R. J., Garneau, K., Levin, R., Lee, J., & Schneeweiss, S. (2010). The comparative safety of opioids for nonmalignant pain in older adults. Archives of Internal Medicine, 170(22), 1979-1986. https://doi.org/10.1001/archinternmed.2010.450

The comparative safety of opioids for nonmalignant pain in older adults. / Solomon, Daniel H.; Rassen, Jeremy A.; Glynn, Robert J.; Garneau, Katie; Levin, Raisa; Lee, Joy; Schneeweiss, Sebastian.

In: Archives of Internal Medicine, Vol. 170, No. 22, 13.12.2010, p. 1979-1986.

Research output: Contribution to journalArticle

Solomon, DH, Rassen, JA, Glynn, RJ, Garneau, K, Levin, R, Lee, J & Schneeweiss, S 2010, 'The comparative safety of opioids for nonmalignant pain in older adults', Archives of Internal Medicine, vol. 170, no. 22, pp. 1979-1986. https://doi.org/10.1001/archinternmed.2010.450
Solomon, Daniel H. ; Rassen, Jeremy A. ; Glynn, Robert J. ; Garneau, Katie ; Levin, Raisa ; Lee, Joy ; Schneeweiss, Sebastian. / The comparative safety of opioids for nonmalignant pain in older adults. In: Archives of Internal Medicine. 2010 ; Vol. 170, No. 22. pp. 1979-1986.
@article{ce749dce693b47f0a6b4f7197abe9c84,
title = "The comparative safety of opioids for nonmalignant pain in older adults",
abstract = "Background: Severe nonmalignant pain affects a large proportion of adults. Optimal treatment is not clear, and opioids are an important option for analgesia. However, there is relatively little information about the comparative safety of opioids. Therefore, we sought to compare the safety of opioids commonly used for nonmalignant pain. Methods: We devised a propensity-matched cohort analysis that used health care utilization data collected from January 1, 1996, through December 31, 2005. Study participants were Medicare beneficiaries from 2 US states who were new initiators of opioid therapy for nonmalignant pain, including codeine phosphate, hydrocodone bitartrate, oxycodone hydrochloride, propoxyphene hydrochloride, and tramadol hydrochloride; none had a cancer diagnosis, and none were using hospice or nursing home care. Our main outcome measures were incidence rates and rate ratios (RRs) with 95{\%} confidence intervals (CIs) for cardiovascular events, fractures, gastrointestinal events, and several composite end points. Results: We matched 6275 subjects in each of the 5 opioid groups. The groups were well matched on baseline characteristics. The risk of cardiovascular events was similar across opioid groups 30 days after the start of opioid therapy, but it was elevated for codeine (RR, 1.62; 95{\%} CI, 1.27-2.06) after 180 days. Compared with hydrocodone, after 30 days of opioid exposure the risk of fracture was significantly reduced for tramadol (RR, 0.21; 95{\%} CI, 0.16-0.28) and propoxyphene (0.54; 0.44-0.66) users. The risk of gastrointestinal safety events did not differ across opioid groups. All-cause mortality was elevated after 30 days for oxycodone (RR, 2.43; 95{\%} CI, 1.47-4.00) and codeine (2.05; 1.22-3.45) users compared with hydrocodone users. Conclusions: The rates of safety events among older adults using opioids for nonmalignant pain vary significantly by agent. Causal inference requires experimental designs, but these results should prompt caution and further study.",
author = "Solomon, {Daniel H.} and Rassen, {Jeremy A.} and Glynn, {Robert J.} and Katie Garneau and Raisa Levin and Joy Lee and Sebastian Schneeweiss",
year = "2010",
month = "12",
day = "13",
doi = "10.1001/archinternmed.2010.450",
language = "English (US)",
volume = "170",
pages = "1979--1986",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "22",

}

TY - JOUR

T1 - The comparative safety of opioids for nonmalignant pain in older adults

AU - Solomon, Daniel H.

AU - Rassen, Jeremy A.

AU - Glynn, Robert J.

AU - Garneau, Katie

AU - Levin, Raisa

AU - Lee, Joy

AU - Schneeweiss, Sebastian

PY - 2010/12/13

Y1 - 2010/12/13

N2 - Background: Severe nonmalignant pain affects a large proportion of adults. Optimal treatment is not clear, and opioids are an important option for analgesia. However, there is relatively little information about the comparative safety of opioids. Therefore, we sought to compare the safety of opioids commonly used for nonmalignant pain. Methods: We devised a propensity-matched cohort analysis that used health care utilization data collected from January 1, 1996, through December 31, 2005. Study participants were Medicare beneficiaries from 2 US states who were new initiators of opioid therapy for nonmalignant pain, including codeine phosphate, hydrocodone bitartrate, oxycodone hydrochloride, propoxyphene hydrochloride, and tramadol hydrochloride; none had a cancer diagnosis, and none were using hospice or nursing home care. Our main outcome measures were incidence rates and rate ratios (RRs) with 95% confidence intervals (CIs) for cardiovascular events, fractures, gastrointestinal events, and several composite end points. Results: We matched 6275 subjects in each of the 5 opioid groups. The groups were well matched on baseline characteristics. The risk of cardiovascular events was similar across opioid groups 30 days after the start of opioid therapy, but it was elevated for codeine (RR, 1.62; 95% CI, 1.27-2.06) after 180 days. Compared with hydrocodone, after 30 days of opioid exposure the risk of fracture was significantly reduced for tramadol (RR, 0.21; 95% CI, 0.16-0.28) and propoxyphene (0.54; 0.44-0.66) users. The risk of gastrointestinal safety events did not differ across opioid groups. All-cause mortality was elevated after 30 days for oxycodone (RR, 2.43; 95% CI, 1.47-4.00) and codeine (2.05; 1.22-3.45) users compared with hydrocodone users. Conclusions: The rates of safety events among older adults using opioids for nonmalignant pain vary significantly by agent. Causal inference requires experimental designs, but these results should prompt caution and further study.

AB - Background: Severe nonmalignant pain affects a large proportion of adults. Optimal treatment is not clear, and opioids are an important option for analgesia. However, there is relatively little information about the comparative safety of opioids. Therefore, we sought to compare the safety of opioids commonly used for nonmalignant pain. Methods: We devised a propensity-matched cohort analysis that used health care utilization data collected from January 1, 1996, through December 31, 2005. Study participants were Medicare beneficiaries from 2 US states who were new initiators of opioid therapy for nonmalignant pain, including codeine phosphate, hydrocodone bitartrate, oxycodone hydrochloride, propoxyphene hydrochloride, and tramadol hydrochloride; none had a cancer diagnosis, and none were using hospice or nursing home care. Our main outcome measures were incidence rates and rate ratios (RRs) with 95% confidence intervals (CIs) for cardiovascular events, fractures, gastrointestinal events, and several composite end points. Results: We matched 6275 subjects in each of the 5 opioid groups. The groups were well matched on baseline characteristics. The risk of cardiovascular events was similar across opioid groups 30 days after the start of opioid therapy, but it was elevated for codeine (RR, 1.62; 95% CI, 1.27-2.06) after 180 days. Compared with hydrocodone, after 30 days of opioid exposure the risk of fracture was significantly reduced for tramadol (RR, 0.21; 95% CI, 0.16-0.28) and propoxyphene (0.54; 0.44-0.66) users. The risk of gastrointestinal safety events did not differ across opioid groups. All-cause mortality was elevated after 30 days for oxycodone (RR, 2.43; 95% CI, 1.47-4.00) and codeine (2.05; 1.22-3.45) users compared with hydrocodone users. Conclusions: The rates of safety events among older adults using opioids for nonmalignant pain vary significantly by agent. Causal inference requires experimental designs, but these results should prompt caution and further study.

UR - http://www.scopus.com/inward/record.url?scp=78650126900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650126900&partnerID=8YFLogxK

U2 - 10.1001/archinternmed.2010.450

DO - 10.1001/archinternmed.2010.450

M3 - Article

C2 - 21149754

AN - SCOPUS:78650126900

VL - 170

SP - 1979

EP - 1986

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 22

ER -